Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines
GlaxoSmithKline (NYSE: GSK) today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting.
GSK announces Q1 results for 2010
GSK delivers Q1 EPS of 30.7p +16% CER before major restructuring
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) and today announced topline secondary endpoints from BLISS-76.
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab)
GSK and Genmab AS confirmed that EC has granted a conditional marketing authorisation for Arzerra for the treatment of refractory CLL.
GSK receives European approval for Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases
GSK has right to license and commercialise compounds at clinical proof-of-concept
GSK regulatory update – Avodart (dutasteride)
GSK announced today that it has re-submitted sNDA for Avodart (dutasteride) for prostate cancer risk reduction among men.
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs.
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that the European Medicines Agency (EMA) has maintained its position.
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries
Unique finance mechanism ensures vaccinations will begin in 2010 - Up to 300 million doses to be supplied over ten years.
GlaxoSmithKline announces Swiss approval of Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1.
GSK announces succession plan for leadership of Consumer Healthcare business
Emma Walmsley appointed President, Consumer Healthcare Europe and President Designate, Worldwide Consumer Healthcare
GlaxoSmithKline commences Relovair Phase III asthma programme
GlaxoSmithKline (GSK) announced today that the first asthma patient has commenced treatment with Relovair.
GSK publishes 2009 Corporate Responsibility Report
In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly.
GSK commences succession plan for management of vaccines business
GlaxoSmithKline (GSK) today announced management changes related to its Vaccines business as part of a planned succession strategy.
GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted marketing authorisation for Revolade.
GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF
(GSK) CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole.
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia
GSK responded to the released Senate Committee on Finance January 2010 Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia.
GSK rejects conclusions reported in The New York Times story on Avandia
GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in New York Times story.